October 9, 2007

Genovis’ Online Sales Generate First Revenues and Open Doors to New Markets

Regulatory

Lund-based biotech company Genovis, which develops and markets innovative tools for medical research, launched its web shop in late September. Genovis’ products, various nanoparticles that are so small that they are not even visible under microscope, have not previously been available for sale. Customers are mainly found in preclinical research in both academia and industry.

During the first few weeks the site attracted interest from Europe, the US, Australia, India, Korea, Singapore, Brazil, and Mexico, which now generate the first revenues. These markets are prioritized markets were Genovis intends to be represented. The new web site will help partners and distributors in their customer relationship management initiatives.

“Establishing online sales has been our strategy since the first test launch one year ago,” says Sarah Fredriksson, CEO. “Now we have a web site for online sales, as well as an underlying system and resources to be able to offer our customers good service and support. The web store will also facilitate future alliances with partners and distributors in different geographic markets.”

Genovis currently offers products in two business areas: biomolecule delivery and antibody engineering, as well as customer-specific solutions. The company’s product portfolio contains the following products: NIMT® FeOsilence, NIMT® FeOfection, NIMT® FeOlabeling, and NIMT® FabRICATOR. The company plans to launch additional products during the autumn.

wkr0022.pdf